These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34133089)

  • 21. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
    Fourrier C; Sampson E; Mills NT; Baune BT
    Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR; Jacobsen PL; Chen Y
    Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of vortioxetine on the physical symptoms of major depressive disorder.
    Christensen MC; Florea I; Lindsten A; Baldwin DS
    J Psychopharmacol; 2018 Oct; 32(10):1086-1097. PubMed ID: 30047820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
    Baune BT; Sluth LB; Olsen CK
    J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study.
    Vieta E; Florea I; Schmidt SN; Areberg J; Ettrup A
    Int Clin Psychopharmacol; 2019 Jul; 34(4):153-160. PubMed ID: 31094901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder.
    Wang G; Zhao K; Reynaud-Mougin C; Loft H; Ren H; Eriksen HF; Ettrup A
    Curr Med Res Opin; 2020 May; 36(5):875-882. PubMed ID: 31990207
    [No Abstract]   [Full Text] [Related]  

  • 27. The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis.
    Fu J; Chen Y
    Psychopharmacology (Berl); 2015 Jan; 232(1):7-16. PubMed ID: 24871704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 7-day randomized, double-blind, placebo-controlled exploratory study.
    Rancans E; Zambori J; Dalsgaard M; Baayen C; Areberg J; Ettrup A; Florea I
    Int Clin Psychopharmacol; 2020 Nov; 35(6):305-312. PubMed ID: 32784346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial.
    Baune BT; Sampson E; Louise J; Hori H; Schubert KO; Clark SR; Mills NT; Fourrier C
    Eur Neuropsychopharmacol; 2021 Dec; 53():34-46. PubMed ID: 34375789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder.
    Kennedy SH; Grouin JM; Cadour S; Robert V; Picarel-Blanchot F
    Hum Psychopharmacol; 2018 Jan; 33(1):. PubMed ID: 29327372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma.
    Christensen MC; Florea I; Loft H; McIntyre RS
    J Affect Disord; 2020 Feb; 263():258-266. PubMed ID: 31818787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
    Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
    Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder.
    Liebowitz MR; Careri J; Blatt K; Draine A; Morita J; Moran M; Hanover R
    Depress Anxiety; 2017 Dec; 34(12):1164-1172. PubMed ID: 29166552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Central monitoring of depression and anxiety symptoms reduces placebo responses in depression clinical trials: A post hoc exploratory analysis of data from the phase III CCT-004 trial of vortioxetine.
    Watanabe Y; Nishimura A; Kikuchi T; Sawada N; Imazaki M; Inada I; Watanabe K
    Neuropsychopharmacol Rep; 2022 Dec; 42(4):468-477. PubMed ID: 36151855
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vortioxetine 5, 10, and 20 mg significantly reduces the risk of relapse compared with placebo in patients with remitted major depressive disorder: The RESET study.
    Thase ME; Jacobsen PL; Hanson E; Xu R; Tolkoff M; Murthy NV
    J Affect Disord; 2022 Apr; 303():123-130. PubMed ID: 35131363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study.
    Christensen MC; Schmidt S; Grande I
    J Psychopharmacol; 2022 May; 36(5):566-577. PubMed ID: 35499104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of the University of California San Diego Performance-based Skills Assessment (UPSA) in major depressive disorder: Replication and extension of initial findings.
    Christensen MC; Sluth LB; McIntyre RS
    J Affect Disord; 2019 Feb; 245():508-516. PubMed ID: 30439678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
    J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vilazodone efficacy in subgroups of patients with major depressive disorder: a post-hoc analysis of four randomized, double-blind, placebo-controlled trials.
    Kornstein S; Chang CT; Gommoll CP; Edwards J
    Int Clin Psychopharmacol; 2018 Jul; 33(4):217-223. PubMed ID: 29608461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.